Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) Expected to Post Earnings of $0.06 Per Share

Equities analysts expect Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) to post earnings per share of $0.06 for the current fiscal quarter, according to Zacks Investment Research. Four analysts have provided estimates for Amphastar Pharmaceuticals’ earnings, with the highest EPS estimate coming in at $0.11 and the lowest estimate coming in at ($0.01). Amphastar Pharmaceuticals posted earnings of $0.12 per share during the same quarter last year, which would indicate a negative year-over-year growth rate of 50%. The firm is expected to report its next quarterly earnings results on Thursday, November 14th.

According to Zacks, analysts expect that Amphastar Pharmaceuticals will report full year earnings of $0.30 per share for the current fiscal year, with EPS estimates ranging from $0.19 to $0.41. For the next year, analysts expect that the company will report earnings of $0.97 per share, with EPS estimates ranging from $0.63 to $1.38. Zacks’ EPS averages are a mean average based on a survey of sell-side research firms that follow Amphastar Pharmaceuticals.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last issued its quarterly earnings data on Wednesday, August 7th. The company reported $0.08 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.03 by $0.05. The business had revenue of $79.00 million for the quarter, compared to the consensus estimate of $78.90 million. Amphastar Pharmaceuticals had a return on equity of 5.52% and a net margin of 16.33%. The firm’s revenue was up 11.3% compared to the same quarter last year. During the same period last year, the business earned $0.03 EPS.

Several brokerages have commented on AMPH. BidaskClub raised Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday. TheStreet raised Amphastar Pharmaceuticals from a “c” rating to a “b-” rating in a research report on Wednesday, August 7th. Wells Fargo & Co set a $29.00 price target on Amphastar Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, June 6th. Finally, Zacks Investment Research raised Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating and set a $23.00 price target on the stock in a research report on Wednesday, July 10th. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Amphastar Pharmaceuticals presently has a consensus rating of “Buy” and an average price target of $24.64.

In other news, SVP Yakob Liawatidewi sold 5,000 shares of Amphastar Pharmaceuticals stock in a transaction that occurred on Tuesday, August 13th. The stock was sold at an average price of $20.73, for a total transaction of $103,650.00. Following the sale, the senior vice president now owns 47,188 shares of the company’s stock, valued at approximately $978,207.24. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Jason B. Shandell sold 6,615 shares of Amphastar Pharmaceuticals stock in a transaction that occurred on Wednesday, July 10th. The stock was sold at an average price of $20.31, for a total value of $134,350.65. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 26,557 shares of company stock worth $549,583. Company insiders own 30.80% of the company’s stock.

Several large investors have recently made changes to their positions in the company. BlackRock Inc. grew its holdings in shares of Amphastar Pharmaceuticals by 1.5% during the 2nd quarter. BlackRock Inc. now owns 5,927,141 shares of the company’s stock worth $125,124,000 after purchasing an additional 87,107 shares in the last quarter. Vanguard Group Inc. grew its holdings in shares of Amphastar Pharmaceuticals by 2.5% during the 2nd quarter. Vanguard Group Inc. now owns 2,381,761 shares of the company’s stock worth $50,279,000 after purchasing an additional 57,349 shares in the last quarter. Federated Investors Inc. PA grew its holdings in shares of Amphastar Pharmaceuticals by 8.7% during the 1st quarter. Federated Investors Inc. PA now owns 1,472,931 shares of the company’s stock worth $30,092,000 after purchasing an additional 117,480 shares in the last quarter. Renaissance Technologies LLC grew its holdings in shares of Amphastar Pharmaceuticals by 33.2% during the 2nd quarter. Renaissance Technologies LLC now owns 588,000 shares of the company’s stock worth $12,413,000 after purchasing an additional 146,400 shares in the last quarter. Finally, Nuveen Asset Management LLC acquired a new stake in shares of Amphastar Pharmaceuticals during the 2nd quarter worth approximately $12,134,000. 48.12% of the stock is currently owned by institutional investors.

NASDAQ AMPH traded down $0.32 during trading on Friday, hitting $22.24. The company’s stock had a trading volume of 222,871 shares, compared to its average volume of 205,640. The company has a quick ratio of 1.83, a current ratio of 2.81 and a debt-to-equity ratio of 0.13. The firm has a 50 day moving average price of $20.40 and a 200 day moving average price of $21.31. The firm has a market cap of $1.07 billion, a P/E ratio of 105.90 and a beta of 1.35. Amphastar Pharmaceuticals has a 52 week low of $17.71 and a 52 week high of $25.43.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States and France. The company operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients products.

Featured Story: What is the significance of the death cross?

Get a free copy of the Zacks research report on Amphastar Pharmaceuticals (AMPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Amphastar Pharmaceuticals (NASDAQ:AMPH)

Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.